AZD-5438
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 1mL(10 mM in DMSO) | ¥590.00 | 现货 | |
| 10mg | ¥545.00 | 现货 | |
| 50mg | ¥2000.00 | 现货 | |
| 100mg | ¥3545.00 | 现货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
AZD5438是一种有效的细胞周期蛋白依赖性激酶(CDK)1、2和9的小分子抑制剂,IC50值分别为16 nmol/L、6 nmol/L和20 nmol/L。AZD5438也有效抑制人cyclin E/CDK2复合体,cyclin B1/CDK1复合体和cyclin A/CDK2复合体,IC50值分别为0.006 μM、0.016 μM和0.045 μM。据报道,AZD5438在少数人类肿瘤细胞系中具有显著的抗增殖活性,IC50范围介于0.2 μmol/L到1.7 μmol/L之间,AZD5438也抑制几个蛋白的磷酸化,包括CDK底物pRb、nucleolin、蛋白磷酸酶1a和RNA聚合酶II COOH-端结构域,并诱导G2-M、S和G1细胞周期停滞。
参考文献:
[1]Camidge DR1, Smethurst D, Growcott J, Barrass NC, Foster JR, Febbraro S, Swaisland H, Hughes A. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemother Pharmacol. 2007 Aug;60(3):391-8. Epub 2006 Nov 18.
[2]Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, Oakes S, Green C, Walker M, Newcombe N, Green S, Growcott J, Barker A, Wilkinson RW. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. doi: 10.1158/1535-7163.MCT-08-0836. Epub 2009 Jun 9.
产品性质
| 物理外观 | A solid |
| CAS号 | 602306-29-6 |
| 分子式 | C18H21N5O2S |
| 分子量 | 371.46 |
| 化学名称 | 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine |
| 溶解度 | insoluble in H2O; ≥18.55 mg/mL in DMSO; ≥42.1 mg/mL in EtOH |
| SMILES | CC(C)[n]1c(-c2ccnc(Nc(cc3)ccc3S(C)(=O)=O)n2)cnc1C |
| 存储条件 | -20°C |
| 运输条件 | 蓝冰 |
产品应用 (实验数据来自文献,APExBIO并未验证,仅供参考)
IC50和靶点
| 生物活性描述 | AZD5438是一种有效的CDK1/2/9抑制剂,IC50值为16 nM/6 nM/20 nM。 | ||
| 靶点 | CDK1 | CDK2 | cdk9 |
| 生物活性数据 | 16 nM | 6 nM | 20 nM |
生物相关数据
质量控制
APExBIO 顾客使用本产品发表的 4 篇科研文献
- 1. Kim, Sung O, et al. "The Role of the MEK1/2-ERK-RSK Signalling Axis in Innate Immune Memory." (2023). Electronic Thesis and Dissertation Repository. 9498.
- 2. Rachel Low , Soon-Duck Ha, et al. "Prolonged Inhibition of the MEK1/2-ERK Signaling Axis Primes Interleukin-1 Beta Expression through Histone 3 Lysine 9 Demethylation in Murine Macrophages." Int J Mol Sci. 2023 Sep 22;24(19):14428. PMID: 37833877
- 3. Cingöz O, Goff SP. "Cyclin-dependent kinase activity is required for type I interferon production." Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2950-E2959. PMID:29507205
- 4. Yuan J, Jiang YY, et al. "Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma." Cancer Res. 2017 Dec 1;77(23):6614-6626. PMID:28951465



沪公网安备 31011002003500